Background: We investigated the practice patterns of surgery for advanced ovarian cancer (AOC) through relevant international surveys. Methods: After searching for 878 studies on surgery for AOC till 2017, we extracted 18 questions with similar query and answer formats from eight studies. Among them, 5 and 13 were classified as comprehensive and procedure information. Results: In comprehensive information, there was a higher preference for optimal cytoreduction defined as no visible tumor (44%) compared with residual tumors <1 cm (38%) or <2 cm (2%) and omental disease involving the spleen or pancreas was more important as an intraoperative finding precluding optimal cytoreduction (35%) since 2010. The preference for neoadjuvant chemotherapy was the highest at its use for 1-10% (36%), which was preferred in Europe over USA. The positive expectation of preoperative determination of optimal cytoreduction was higher in Europe than in USA (44 vs. 27%; P < 0.05). In procedure information, conventional gynecological surgery was mainly performed by gynecological oncologists, whereas more than 50% of upper abdominal or urological surgeries were conducted by other surgeons. European clinicians showed a higher response rate of diaphragmatic stripping and resection than those from USA (88 vs. 60%; 69 vs. 24%; P < 0.05). Conclusion: No visible tumor as the criterion for optimal cytoreduction was preferred in AOC, and aggressive surgery beyond conventional gynecological surgery tended to be performed by other surgeons. Moreover, the preference of neoadjuvant chemotherapy and the positive expectation of preoperative determination of optimal cytoreduction were higher in Europe than in USA.
Introduction
Ovarian cancer is the most lethal disease among malignancies that occur in the female genital tract. This is because of a lack of effective screening methods (1) and subsequent delayed diagnosis at advanced ovarian cancer (AOC) occurs in two-third patients with the disease (2) . Although age, performance status, disease extent, histologic type, tumor differentiation, volume of ascites and response to platinum agents are known as prognostic factors in AOC patients, most of them are inevitable in the background of genetic mutation and family history, which are unchangeable after diagnosis and nowadays are expected to be improved by new targeted or immunotherapeutic agents beyond the era of chemotherapy (3) .
On the other hand, the extent of cytoreduction among prognostic factors of AOC is still important for the following reasons. First, removal of as much of the tumor as possible improves survival. Resection of bulky tumors may increase sensitivity to chemotherapy because smaller, well-perfused tumors that are more sensitive to drugs remain after surgical removal of resistant tumors (4) . Second, cytoreduction may improve immune competence of patients (5) . Third, the extent of cytoreduction and the maximal diameter of remaining tumors are the only prognostic factors that can be altered by intervention in AOC (6) .
The importance of cytoreduction in AOC has been proven by previous studies (7, 8) , where patients with smaller residual tumor size after cytoreduction showed improved survival, suggesting the importance of radical resection of tumors to overcome drug resistance and tumor biology. However, the scope of optimal cytoreduction for AOC depends on the time and location. Recently, an increase in radicality and a wide spectrum of relevant procedures commonly permit complete cytoreduction in disseminated tumors that were previously considered as inoperable (9) . Moreover, the definition and rates of optimal cytoreduction vary widely among gynecological oncologists and even within institutions (10, 11) . Therefore, this study aimed to investigate practice patterns of cytoreduction and to identify surgical trends for AOC using relevant survey studies.
Methods

Data sources
We searched PubMed, EmBase and Cochrane library to identify survey studies on cytoreduction for AOC between March 1964 and December 2017. The search terms used were as follows: 'ovarian tumor or ovarian neoplasm or ovarian carcinoma or ovarian cancer' and 'survey'. We included relevant studies that met the following criteria: epithelial ovarian cancer; advanced disease; cytoreductive or debulking surgery; and a survey for clinicians, including gynecological oncologists. However, we excluded studies including editorials or letters to the Editor, case reports, review articles and non-English literature.
Selection of studies
After screening the literature, we identified a total of 1041 studies and removed 51 duplicates. Then, we excluded 173 studies because of non-English literature (n = 102), editorials (n = 26), case reports (n = 24), basic research (n = 14) and letters to the Editor (n = 7). We also excluded 791 studies because of biomarkers, screening or diagnosis (n = 218), non-epithelial ovarian cancer (n = 184), assessment of quality of life (n = 92), prophylactic surgery or surgical techniques (n = 86), surgical or drug efficacy (n = 58), epidemiology (n = 49), counseling for patients or patients' perception (n = 45), complications or prevention (n = 24), nursing care (n = 10), postoperative care (n = 10), clinical characteristics of epithelial ovarian cancer (n = 6), nutrition or physical activity (n = 5) and costeffectiveness (n = 4). Additionally, 17 studies were excluded because of the pattern of surgical practice based on a database from patients, not clinicians (n = 12), and the pattern not specified to surgery for primary ovarian cancer. We finally included nine studies from five national surveys (12) (13) (14) (15) (16) and four society-sponsored surveys from European Society of Gynecological Oncology (ESGO) and Society of Gynecologic Oncologists (SGO) in our analysis (17) (18) (19) (20) .
Data extraction
All questions from the nine survey studies were classified into comprehensive and procedure information. Comprehensive information included questions on following items: the number of patients who received cytoreduction annually, the time required for cytoreduction, the definition of optimal cytoreduction, the proportion of primary cytoreduction or neoadjuvant chemotherapy, survival advantage of ultra-radical cytoreduction, barriers or surgical findings precluding optimal cytoreduction, the preference of primary cytoreduction or neoadjuvant chemotherapy, the proportion of optimal cytoreduction and expectation about preoperative determination of optimal cytoreduction.
Moreover, procedure information included questions on the ability to perform specific surgical skills, such as omentectomy, appendectomy, pelvic or para-aortic lymphadenectomy, small or large bowel resection and anastomosis, splenectomy, resection of tumors in the liver or portal triad, ureteral or bladder surgery, en bloc resection of the uterus, rectosigmoid and peritoneum, diaphragm stripping or resection, distal pancreatectomy and ablation of peritoneal implants.
We collected 92 questions from all studies (Supplementary Table 1 ) and then extracted 24 common questions with similar query types in two or more questions (Supplementary Table 2 ). Then, we excluded six questions with different formats of answer and, thereby, one study was excluded (15) . Finally, we included 18 questions from eight survey studies for the current study ( Supplementary Fig 1 and Supplementary Table 3 ) (12) (13) (14) (16) (17) (18) (19) (20) .
Statistical analyses
Dichotomous data extracted from all of the studies were combined and then compared with the chi-square or Fisher's exact test. We used SPSS software version 21.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism version 5.01 (GraphPad Software Inc., San Diego, CA, USA) for analysis. A P value of <0.05 was considered statistically significant.
Results
Characteristics of surveys Table 1 shows characteristics of the eight survey studies included in the current study (EU2011, SA2016, ANZ2011, UK2013, ESGO2012, SGO2010, SGO2004 and SGO2001). Among these studies, six (75%) studies were conducted since 2010 (12) (13) (14) (15) (16) (17) (18) , whereas two (25%) studies were performed before 2010 (19, 20) . Moreover, survey subjects were individual clinicians in seven studies (87.5%) (13, 14, (16) (17) (18) (19) (20) , whereas a center was studied in one study (12.5%) (12) . A total of 1554 subjects responded to the survey and the response rate ranged from 30 to 81%. Table 2 shows the final 18 questions that were extracted for the current study. Among all questions, 5 (27.8%) and 13 (72.2%) studies were classified into comprehensive and procedure information, respectively.
Comprehensive information
In Question 1, four studies (SA2016, ANZ2011, ESGO2012 and SGO2001) showed a higher preference for optimal cytoreduction defined as a residual tumor of <1 cm (48%) than for no visible tumor (30%) or a residual tumor of <2 cm (7%). Despite differences in the preference of definition of optimal debulking, this preference has increased for no visible tumor (44%) compared with a residual tumor of <1 cm (38%) or <2 cm (2%) since 2010 ( Fig. 1) .
In Question 2, the most common barrier to optimal cytoreduction was medical comorbidities (89%), followed by older age (52%), lack of expertise in debulking surgery (44%) and lack of supportive systems (24%), such as the intensive care unit ( Supplementary Fig. 2 ). In Question 3, which included three studies (SA2016, ANZ2011 and SGO2011), confluent diaphragmatic disease was the most frequent intraoperative finding precluding optimal cytoreduction (76%), followed by disease involving the base of the mesentery (75%), bulky para-aortic lymph nodes (22%) and omental disease involving the spleen or pancreas (16%). In particular, only omental disease involving the spleen or pancreas has become more important as an intraoperative finding precluding optimal cytoreduction since 2010 (Fig. 2) .
In Question 4, the rates of negative and positive expectation about preoperative determination of optimal cytoreduction were 53 and 37%, respectively. Although there was no difference in negative expectation between ESGO2012 and SGO2010 (50 vs. 56%), positive expectation was more common in ESGO2012 than in SGO2010 (44 vs. 27%; Supplementary Fig. 3 ). In Question 5, most of the respondents answered that they used neoadjuvant chemotherapy in 1-10% of AOC patients (57%), followed by 11-25% (25%), 26-40% (10%), 41-60% (8%), >75% (5%), 61-75% (4%) of the patients, and no neoadjuvant chemotherapy (3%) in terms of the preference for neoadjuvant chemotherapy. When we compared the preference for neoadjuvant chemotherapy between two studies, ESGO2012 and SGO2010, SGO2010 showed a higher response rate than did ESGO2012 at use of neoadjuvant chemotherapy for 1-10% (57 vs. 21%) and 11-25% (31 vs. 21%) of AOC patients. However, ESGO2012 demonstrated a higher response rate than did SGO2010 at the use of neoadjuvant chemotherapy for 26-40% (13 vs. 5%), 41-60% (12 vs. 2%), 61-75% (5 vs. 1%) and >75% (8 vs. 1%) of the patients (Fig. 3 ).
Procedure information
Among 13 questions of procedure information, 11 questions were regarding who performed gynecological staging procedure (Questions 7-10), bowel or urological surgery (Questions 11-13) and upper abdominal surgery (Questions 14-17). Moreover, the other two questions were regarding whether diaphragmatic stripping or resection was performed (Questions [18] [19] .
With regard to gynecological staging procedure, pelvic or lower para-aortic lymphadenectomy was mainly performed by gynecological oncologists, with no difference between the two studies (SA2016 and ANZ2011) in Question 6. However, 31% of respondents replied that gynecological oncologists performed upper para-aortic lymphadenectomy with a general surgeon, despite the difference in the rate of cooperation between the two studies (SA2016 and ANZ2011) and 28% of them did not conduct upper para-aortic lymphadenectomy in Question 7. In Question 8, 67% of respondents replied that gynecological oncologists performed en bloc resection of the uterus, rectosigmoid colon and peritoneum themselves, despite the difference in the rate of the surgery by only gynecological oncologists between the two studies. However, 63% of respondents did not perform ablation of peritoneal implants, despite the difference of the rate of no ablative treatment between the two studies (SA2016 and ANZ2011) in Question 9 (Table 3) .
For bowel surgery, 51 and 76% of respondents replied that gynecological oncologists performed large and small bowel surgery themselves, respectively. In particular, ANZ2011 showed that bowel surgery was performed by only gynecological oncologists. However, 41% of urological surgeries were conducted by only gynecological oncologists (Table 4) .
With regard to upper abdominal surgery, 5% of parenchymal liver resections in Question 13, 36% of splenectomies in Question 14 and 20% of distal pancreatectomies in Question 15 were conducted by only gynecological oncologists. However, 41% of diaphragmatic stripping was performed by gynecological oncologists. In particular, EU2011 showed a higher rate of diaphragmatic stripping by only gynecological oncologists than did SA2016 and ANZ2011 (69 vs. 15% or 32%) in the question 16 (Table 5) .
Furthermore, 62% of respondents replied that they performed diaphragmatic stripping, while 27% of them did not conduct diaphragmatic resection in Questions 17 and 18. In particular, EU2011 showed a higher rate of diaphragmatic stripping or resection than did SGO2011 (Fig. 4) .
Discussion
Most clinical trials have recently focused on the efficacy of new drugs or their combination on improved survival in patients with AOC because of limitations of conventional chemotherapy and a lack of new surgical strategies other than optimal cytoreduction. However, optimal cytoreduction is still important because it is a prognostic factor that is affected by the skill and effort of clinicians. Therefore, survey studies are useful for investigating the preference of clinicians for the extent and proficiency of tumors in AOC and we could interpret the result of the current study as follows. With regard to the definition of optimal cytoreduction, the preference for no visible tumor has increased compared with a residual tumor <1 or <2 cm since 2010. Patients with AOC who receive complete cytoreduction may show the most favorable prognosis during the era of adjuvant chemotherapy using taxanes and platinums (4, 21) . Moreover, the importance of optimal cytoreduction was shown indirectly in results of International Collaborative Ovarian Neoplasm study 7 (ICON7), where bevacizumab combined • Medical comorbidities • Lack of expertise in cytoreduction • Older age • Lack of supportive system such as the intensive care unit (ICU) (13, 14) 3 What are intraoperative findings precluding optimal cytoreduction in your center?
• Confluent diaphragmatic disease • Omental disease involving spleen or pancreas • Disease involving the base of mesentery • Bulky para-aortic lymph nodes (13, 14, 20) 4 Do you expect you can determine preoperatively if a patient can receive optimal cytoreduction?
• No • Yes (17, 18) 5 What is the percentage of patients receiving neoadjuvant chemotherapy?
• No
(17,18)
Procedure information
6 Who does perform pelvic or lower para-aortic lymphadenectomy in your center?
• Gynecological oncologist • Collaboration with general surgeon • Never (13, 14) 7 Who does perform upper para-aortic lymphadenectomy in your center?
• Gynecological oncologist • Collaboration with general surgeon • Never (13, 14) 8 Who does perform en bloc resection of the uterus, rectosigmoid and peritoneum in your center?
• Gynecological oncologist • Collaboration with general surgeon • Never done (13, 14) 9 Who does perform ablation of peritoneal implants in your center?
• Gynecological oncologist • Collaboration with general surgeon • Never (13, 14) 10 Who does perform large bowel resection in your center?
• Gynecological oncologist • Collaboration with general surgeon (12) (13) (14) 11 Who does perform small bowel resection in your center?
• Gynecological oncologist • Collaboration with general surgeon • Never (13, 14) 12 Who does perform ureteral or bladder surgery in your center?
• Gynecological oncologist • Collaboration with urologist • Never (13, 14) 13 Who does perform resection of parenchymal liver metastases in your center?
• Gynecological oncologist • Collaboration with general surgeon (12) (13) (14) 14 Who does perform splenectomy in your center?
• Gynecological oncologist • Collaboration with general surgeon (12) (13) (14) 15 Who does perform distal pancreatectomy in your center?
• Gynecological oncologist • Collaboration with general surgeon • Never (13, 14) 16 Who does perform diaphragm stripping in your center?
• Gynecological oncologist • Collaboration with general surgeon (12) (13) (14) 17 Do you perform diaphragmatic stripping?
• No • Yes (10, 18) 18 Do you perform diaphragmatic resection?
• No • Yes (10, 18) with chemotherapy did not improve overall survival in patients who received complete cytoreduction, despite survival benefit in those with a high-risk of progression, such as suboptimal cytoreduction (22) . With the increasing preference for no visible tumor as the definition of optimal cytoreduction, we found a change in disturbance factors for optimal cytoreduction. Although there were no differences in the distribution of common barriers to optimal cytoreduction, omental disease involving the spleen or pancreas has become more important as an intraoperative finding precluding complete cytoreduction in clinicians since 2010. Therefore, this factor can increase the preference of neoadjuvant chemotherapy or aggressive surgery for optimal cytoreduction.
With regard to aggressive surgery, conventional gynecological surgery, such as pelvic or lower para-aortic lymphadenectomy and en bloc resection of the uterus, rectosigmoid colon and peritoneum, was mainly performed by gynecological oncologists. However, more than 50% of Figure 1 . Analysis of answers to Question 1, 'what is the definition of optimal cytoreduction?', in comprehensive information. All studies showed a higher preference for optimal cytoreduction defined as a residual tumor <1 cm (48%) than for no visible tumor (30%) or a residual tumor <2 cm (7%). This preference has increased for no visible tumor (44%) compared with a residual tumor <1 cm (38%) or <2 cm (2%) since 2010 (*P < 0.05). Confluent diaphragmatic disease was the most frequent intraoperative finding precluding optimal cytoreduction (76%), followed by disease involving the base of the mesentery (75%), bulky para-aortic lymph nodes (22%) and omental disease involving the spleen or pancreas (16%). Especially, only omental disease involving the spleen or pancreas has become more important as an intraoperative finding precluding optimal cytoreduction since 2010 (*P < 0.05).
upper abdominal or urological surgeries tended to be conducted by other surgeons or their cooperation. Moreover, we thought that the relatively low rate of upper abdominal and urological surgeries performed by gynecological oncologists may be associated with a relative lack of additional training outside of a gynecological fellowship. Therefore, the likelihood of upper abdominal or urological surgery being performed by only gynecological oncologists can be increased by extension of an additional training program.
With regard to neoadjuvant chemotherapy, we found that the preference for neoadjuvant chemotherapy was relatively low because the preference was higher at use of neoadjuvant chemotherapy for 1-10 and 11-25% for AOC patients. However, ESGO2012 showed a higher preference for neoadjuvant chemotherapy than did SGO2010, which suggests that it may be preferred in Europe over USA. The reason can be explained as follows. First, the two, large-scale, randomized, controlled trials Most of the respondents answered that they used neoadjuvant chemotherapy in 1-10% of AOC patients (57%), followed by 11-25% (25%), 26-40% (10%), 41-60% (8%), >75% (5%) and 61-75% (4%) of the patients and no neoadjuvant chemotherapy (3%) in terms of the preference for neoadjuvant chemotherapy. When we compared the preference for neoadjuvant chemotherapy between two studies, ESGO2012 and SGO2010, SGO2010 showed a higher response rate than did ESGO2012 at use of neoadjuvant chemotherapy for 1-10% (57 vs. 21%) and 11-25% (31 vs. 21%) of AOC patients. However, ESGO2012 demonstrated a higher response rate than did SGO2010 at use of neoadjuvant chemotherapy for 26-40% (13 vs. 5%), 41-60% (12 vs. 2%), 61-75% (5 vs. 1%) and >75% (8 vs. 1%) of the patients (*P < 0.05). were performed in Europe (8, 23) , which reflects a relatively high preference for neoadjuvant chemotherapy in European clinicians. Second, our result showed a higher response rate of positive expectation about preoperative determination of optimal cytoreduction and diaphragmatic stripping or resection than those from USA. It means that positive expectation of preoperative determination of optimal cytoreduction can lead to the limitation of primary cytoreduction to patients with AOC inversely because of strict criteria for primary cytoreduction. However, this hypothesis should be proved by whole data about optimal cytoreduction between Europe and USA. The current study has some limitations for analyzing the results from the eight survey studies. First, all of the included studies were heterogenous because of regional differences and the risk of bias among individual studies did not be assessed. In the current study, we considered EU2011 and ESGO2012 as representative studies of European clinicians because their participation rates were 100 and 75.6%, whereas we did SGO2001, SGO2004 and SGO2010 as those of clinicians form USA because the participation rates from USA ranged from 94.6-97% in the three studies. Nevertheless, small numbers of studies are not sufficient to reflect the preferences of clinicians from Europe and the United States, which may make the interpretation of results more obscure. Second, subjects in most of the studies were individual clinicians, whereas a center was studied in EU2011. Third, various response rates among the studies could have introduced bias in the analysis process in the current study. Fourth, the extent and definition of some surgical procedures are ambiguous because of descriptive results based on relevant surveys. For example, the extent of upper para-aortic lymphadenectomy was not clear when compared with lower para-aortic lymphadenectomy and the ablation of peritoneal implants was not defined in comparison with excision of them. Fifth, cooperation with specialists other than gynecological oncologists for bowel, urological and upper abdominal surgery can depend on specific circumstances such as complications before surgery, lack of enough training system and risk of medical-legal litigations different among institutions and countries. Sixth, the difference of surgical proficiency among responders can be act as a bias for evaluating the criteria for optimal cytoreduction and the extent of aggressive surgery, which can affect the preference of neoadjuvant chemotherapy. Thus, stratified analyses based on surgical proficiency should be considered to minimize the bias like trial of radial upfront surgery in AOC (TRUST) trial, where gynecological oncologist showing higher rates of optimal cytoreduction can participate selectively, in the future (24) .
Conclusions
In conclusion, the current study showed that optimal cytoreduction defined as no visible tumor may be increasingly important in AOC and aggressive surgery beyond conventional gynecological surgery may be required because upper abdominal lesions can act as disturbance factors against optimal cytoreduction. Moreover, the preference of neoadjuvant chemotherapy and the positive expectation of preoperative determination of optimal cytoreduction tend to be higher in Europe than in USA.
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